COMPANY PROFILE

OrSense

Explore full profile

Innovative non-invasive hemoglobin measurement solutions for blood banks and medical facilities

Ness Ziyyona, IsraelFounded 1997Biotech & Life Sciences

Valuation $50–100M Last recorded · 2011

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About OrSense

OrSense is a medical technology company specializing in non-invasive hemoglobin measurement solutions. The company serves blood banks, hospitals, and other medical facilities, providing advanced devices that measure hemoglobin levels without the need for blood samples. Operating in the healthcare market, OrSense's business model revolves around the sale and distribution of its proprietary medical devices. Revenue is generated through direct sales, partnerships, and long-term service agreements with healthcare providers. The company's technology is particularly valuable in settings such as blood donation centers, intensive care units (ICUs), and operating rooms, where quick and accurate hemoglobin measurement is critical. OrSense's innovative approach not only enhances patient care but also improves operational efficiency for medical staff. Keywords: Non-invasive, Hemoglobin, Blood banks, Medical devices, Healthcare, ICU, Blood donation, Patient care, Hematology, Medical technology.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 1997
Headquarters: Ness Ziyyona, Israel
Employees: 26
Open positions: None listed
Dealroom signal: 78.7/100
Industry: Health
Sub-industry: BioTechnology, Medical Devices
Sector: Biotech & Life Sciences, Diabetes, Testing, Biotechnology, Remote Monitoring, Non-Invasive medical devices and treatments, Tech for Patients, Biotech and Pharma, Hard Tech
Technology: Deep Tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES HEquity / VC	Feb 2015	$0	—	Saints Capital	—
DEBTDebt	Jan 2014	$0	—	Saints Capital	—

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

OrSense website traffic

Latest recorded traffic for OrSense is 2.1K monthly website visits, up 16.7% over the last three months. OrSense's team grew 4% over the past year.

Latest monthly visits2.1K 3-month web change+16.7% 1-year team growth+4%

Monthly website visitsOct 2014–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
OUOutsenseOutSense has developed a novel technology capable of accurately analyzing and diagnosing human waste from within a standard toilet bowl	Or Yehuda, Israel	Operational	23	$2.9M	$11M
COColorimetrixColorimetrix offers a unique, low-cost, accurate method of reading “colorimetric tests” using a mobile phone. Colorimetric tests are used across a wide variety of applications such as pregnancy tests, urine monitoring, and an enormous amount of other	Garching bei München, Germany	Operational
GLGlookoUnified platform for diabetes management	Palo Alto, United States	Operational
MOmoveUPAI-powered digital therapy for remote patient monitoring	City of Brussels, Belgium	Operational
DIDiabeloopMedical device company for diabetes and closed-loop system and also develops disruptive technological innovations to automate the treatment of diabetes	Grenoble, France	Operational
ETElfi TechHas developed an innovative finger based device for convenient and accurate measurement of blood pressure	Ramat Gan, Israel	Operational
PUPulmOneInnovative tabletop device for accurate, rapid pulmonary function testing with full reimbursement eligibility in the USA	Ra'anana, Israel	Operational
BTBetalin therapeuticsBetalin's Micro Pancreas is a revolutionary regenerative micro-organ based on cell therapy. It eliminates the need for daily injections, constant blood glucose monitoring, and dietary constraints	Ramat Gan, Israel	Operational